Lobbying disclosures · Lobbying report
REGN: third_quarter 2026 lobbying report
Intellectual property legislation related to biopharmaceutical manufacturers. Trade and tariff issues related to corporations; outbound investment restrictions related to biopharmaceutical manufacturers. Tax and inflation issues related to corporations. Privacy legislation related to biopharmaceutical manufacturers; Food and Drug Administration and manufacturing issues related to biopharmaceutical manufacturers; National security issues related to biopharmaceutical manufacturers; Public-private contracts for innovation in the biopharmaceutical space; Biosimilar issues related to biopharmaceuti
Follow REGN- Became public
- Oct 20, 2026, 8:39 PM EDT
- Event / period date
- Not stated
- Collected
- Nov 12, 2026, 12:38 AM EST
Why this is connected
Exact legal-name match: REGENERON PHARMACEUTICALS, INC. (https://www.sec.gov/Archives/edgar/data/872589/).
Reported lobbying amounts
Expenses: $590,000.00
These are different reporting measures. They are not added together or treated as spending on one particular bill.
Source evidence
Read the source excerpt or record
{"url":"https://lda.gov/api/v1/filings/28bf8ef6-d70b-409d-93a8-b17bd3417bcd/","filing_uuid":"28bf8ef6-d70b-409d-93a8-b17bd3417bcd","filing_type":"Q3","filing_type_display":"3rd Quarter - Report","filing_year":2026,"filing_period":"third_quarter","filing_period_display":"3rd Quarter (July 1 - Sep 30)","filing_document_url":"https://lda.gov/filings/public/filing/28bf8ef6-d70b-409d-93a8-b17bd3417bcd/print/","filing_document_content_type":"text/html","income":null,"expenses":"590000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Maya J. Bermingham","dt_posted":"2026-10-20T20:39:27-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"777 OLD SAW MILL RIVER ROAD","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"TARRYTOWN","registrant_state":"NY","registrant_zip":"10591","registrant":{"id":401104131,"url":"https://lda.gov/api/v1/registrants/401104131/","house_registrant_id":null,"name":"REGENERON PHARMACEUTICALS, INC","description":"Biopharmaceutical development and manufacturing","address_1":"777 OLD SAW MILL RIVER ROAD","address_2":null,"address_3":null,"address_4":null,"city":"TARRYTOWN","state":"NY","state_display":"New York","zip":"10591","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"MAYA J. BERMINGHAM","contact_telephone":"+1 914-598-3031","dt_updated":"2026-07-29T09:39:25.971423-04:00"},"client":{"id":200807,"url":"https://lda.gov/api/v1/clients/200807/","client_id":12,"name":"REGENERON PHARMACEUTICALS, INC","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"NY","state_display":"New York","country":"US","country_display":"United States of America","ppb_state":"NY","ppb_state_display":"New York","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2016-08-01"},"lobbying_activities":[{"general_issue_code":"CPT","general_issue_code_display":"Copyright/Patent/Trademark","description":"Intellectual property legislation related to biopharmaceutical manufacturers.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":140575,"prefix":null,"prefix_display":null,"first_name":"EBEN","nickname":null,"middle_name":null,"last_name":"DUROSS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":140574,"prefix":null,"prefix_display":null,"first_name":"MADDIE","nickname":null,"middle_name":null,"last_name":"DAVIDSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":71871,"prefix":null,"prefix_display":null,"first_name":"KATHERINE","nickname":null,"middle_name":null,"last_name":"HADDAD","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TRD","general_issue_code_display":"Trade (domestic/foreign)","description":"Trade and tariff issues related to corporations; outbound investment restrictions related to biopharmaceutical manufacturers.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":140574,"prefix":null,"prefix_display":null,"first_name":"MADDIE","nickname":null,"middle_name":null,"last_name":"DAVIDSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":140575,"prefix":null,"prefix_display":null,"first_name":"EBEN","nickname":null,"middle_name":null,"last_name":"DUROSS","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"Tax and inflation issues related to corporations.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":140575,"prefix":null,"prefix_display":null,"first_name":"EBEN","nickname":null,"middle_name":null,"last_name":"DUROSS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":71871,"prefix":null,"prefix_display":null,"first_name":"KATHERINE","nickname":null,"middle_name":null,"last_name":"HADDAD","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":140574,"prefix":null,"prefix_display":null,"first_name":"MADDIE","nickname":null,"middle_name":null,"last_name":"DAVIDSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Privacy legislation related to biopharmaceutical manufacturers; Food and Drug Administration and manufacturing issues related to biopharmaceutical manufacturers; National security issues related to biopharmaceutical manufacturers; Public-private contracts for innovation in the biopharmaceutical space; Biosimilar issues related to biopharmaceutical manufacturers.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":140574,"prefix":null,"prefix_display":null,"first_name":"MADDIE","nickname":null,"middle_name":null,"last_name":"DAVIDSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":140575,"prefix":null,"prefix_display":null,"first_name":"EBEN","nickname":null,"middle_name":null,"last_name":"DUROSS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":71871,"prefix":null,"prefix_display":null,"first_name":"KATHERINE","nickname":null,"middle_name":null,"last_name":"HADDAD","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Medicare, Medicaid, and other drug pricing issues relating to biopharmaceutical manufacturers.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":140574,"prefix":null,"prefix_display":null,"first_name":"MADDIE","nickname":null,"middle_name":null,"last_name":"DAVIDSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":71871,"prefix":null,"prefix_display":null,"first_name":"KATHERINE","nickname":null,"middle_name":null,"last_name":"HADDAD","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}Congressional trading in REGN
These disclosures provide context. Their presence does not establish a link between a trader and the event.
- Nov 5, 2026$1K–$15K
Rep. Ro Khanna (D-CA-17)
Bought Regeneron Pharmaceuticals REGN
$1K–$15K · Traded Oct 7, 2026 · disclosed Nov 5, 2026 · Spouse
- Oct 7, 2026$1K–$15K
Rep. Ro Khanna (D-CA-17)
Sold Regeneron Pharmaceuticals REGN
$1K–$15K · Traded Sep 4, 2026 · disclosed Oct 7, 2026 · Spouse
- Jul 21, 2026$1K–$15K
Sen. Alan Armstrong (R-OK)
Bought Regeneron Pharmaceuticals REGN
$1K–$15K · Traded Mar 27, 2026 · disclosed Jul 21, 2026 · filed 116 days later
Committee overlap: HELP - Jun 8, 2026$1K–$15K
Rep. Gilbert Ray Cisneros, Jr. (D-CA-31)
Sold Regeneron Pharmaceuticals REGN
$1K–$15K · Traded May 15, 2026 · disclosed Jun 8, 2026
- May 11, 2026$1K–$15K
Rep. Ro Khanna (D-CA-17)
Bought Regeneron Pharmaceuticals REGN
$1K–$15K · Traded Apr 13, 2026 · disclosed May 11, 2026 · Spouse
- Mar 12, 2026$1K–$15K
Rep. Julia Letlow (R-LA-5)
Bought Regeneron Pharmaceuticals REGN
$1K–$15K · Traded Feb 12, 2026 · disclosed Mar 12, 2026
- Feb 6, 2026$1K–$15K
Rep. Ro Khanna (D-CA-17)
Sold Regeneron Pharmaceuticals REGN
$1K–$15K · Traded Jan 29, 2026 · disclosed Feb 6, 2026 · Spouse
- Dec 15, 2025$1K–$15K
Rep. Gilbert Ray Cisneros, Jr. (D-CA-31)
Bought Regeneron Pharmaceuticals REGN
$1K–$15K · Traded Nov 18, 2025 · disclosed Dec 15, 2025
Original documents control. Public records can be amended, and company connections may require interpretation. Nothing here is investment advice.